Laboratory Reference Grade Compounds
Metabolic & Weight Management Peptides

AOD-9604

RUO In-VitroLyophilized Powder≥99% Reference Standard
Protocol SOP↓
₱3,400.00
In Stock · Dispatches 24h
InclusionVial Only
Net Content5MG
Volume Discounts:Up to 20% OFF
1
SOPReconstitution Telemetry (5MG)
Diluent:mL
Concentration5.00 mg/mLin 1.0mL BAC
Standard Dose300 mcg – 500 mcg dailySyringe: 12.0 units (0.12 mL)
Scale (1 Unit)50 mcgper 0.01 mL (U-100)
• Lyophilized vial onlyMonograph SOP →
AOD-96045MG · Vial Only
₱3,400.00
1
Technical Specification & Protocol Dossier

Analytical Standards & Laboratory Handling

Verified laboratory protocols, reconstitution parameters, and handling guidelines.

P

Pharmacological Profile & Mechanism of Action

Research Monograph

What it is: AOD-9604 (Advanced Obesity Drug-9604) is a synthetic 16-amino-acid peptide derived from the C-terminal region (amino acids 177–191) of human growth hormone, with an added tyrosine residue for stability.

How it works: It isolates the fat-burning (lipolytic) domain of growth hormone without interacting with the growth hormone receptor. This means it triggers fat breakdown (lipolysis) and stops new fat storage (lipogenesis) without increasing IGF-1, without affecting blood sugar, and without promoting organ enlargement or cellular proliferation.

Why researchers study it: Studied for targeted fat loss without hormonal side effects, cartilage and joint regeneration, repairing osteoarthritis damage, and metabolic health with an exceptional safety profile.

Compound & Molecular Specifications

Certificate of Analysis Standards
Target CategoryMetabolic Signaling & Incretins
Intended ApplicationLaboratory & In-Vitro Research Only (RUO)
Physical StateLyophilized Solid Powder
CAS Registry Number221231-10-3
PubChem CID71300630↗
Molecular Weight1815.1 g/mol
Purity Specification≥99.0% (HPLC-grade)
Net Content Options2MG, 5MG, 10MG
Inclusion PackagesVial Only, Vial + BAC Water, Analytical Lab Set
Peptide Sequence / FormulaTyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (Disulfide bridge Cys7-Cys14)
⚡ Pharmacodynamic Synergy·Verified Stacking Regimens

Frequently Stacked with AOD-9604 (Lipolytic Fragment)

Clinically verified combinations activating complementary physiological pathways without receptor competition.

Stacking Studio
Co-Administered Regimen

Tirzepatide

+94 Synergy
Metabolic Dual-Action Stack: Incretin Satiety + Beta-3 Adipocyte Lipolysis

Tirzepatide centrally suppresses appetite, improves glycemic control, and downregulates hepatic de novo lipogenesis via GLP-1/GIP. AOD-9604 acts peripherally on adipocyte beta-3 adrenergic receptors to trigger active lipolysis and fat breakdown without interfering with blood glucose or insulin sensitivity.

⏱Tirzepatide: 1x weekly SubQ•🛡Separate syringe
15% Off bundle
Compare